SCHEMBL7109645

SCHEMBL7109645

CCCC(=O)OCOC(=S)/C=C/c1ccccc1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 2/20 0.44
L3MBTL1 Q9Y468 1/20 0.44
TDP1 Q9NUW8 2/20 0.44
GLA P06280 1/20 0.44
LMNA P02545 3/20 0.43
HTT P42858 1/20 0.43
ALDH1A1 P00352 3/20 0.43
HDAC3 O15379 2/20 0.42
SMN1; SMN2 Q16637 2/20 0.42
MAPT P10636 2/20 0.42
TNKS O95271 1/20 0.42
HDAC4 P56524 1/20 0.42
HDAC1 Q13547 1/20 0.42
HCAR2 Q8TDS4 1/20 0.42
HDAC7 Q8WUI4 1/20 0.42
HDAC2 Q92769 1/20 0.42
HDAC10 Q969S8 1/20 0.42
HDAC11 Q96DB2 1/20 0.42
HDAC8 Q9BY41 1/20 0.42
TNKS2 Q9H2K2 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7109642 1.00 NPC1 (0.44) NPC1L3MBTL1TDP1GLALMNA
SCHEMBL6924525 0.85 LMNA (0.56) NPC1L3MBTL1TDP1GLALMNA
SCHEMBL6924526 0.85 LMNA (0.56) NPC1L3MBTL1TDP1GLALMNA
SCHEMBL7108324 0.79 LMNA (0.52) NPC1L3MBTL1TDP1GLALMNA
SCHEMBL7109640 0.76 NPC1 (0.43) NPC1L3MBTL1TDP1GLALMNA
SCHEMBL29010570 0.76 LMNA (0.51) NPC1L3MBTL1TDP1GLALMNA
SCHEMBL356660 0.76 MMP1 (0.49) NPC1TDP1ALDH1A1SMN1; SMN2MAPT
SCHEMBL356661 0.76 MMP1 (0.49) NPC1TDP1ALDH1A1SMN1; SMN2MAPT
SCHEMBL14763825 0.76 MMP1 (0.49) NPC1TDP1ALDH1A1SMN1; SMN2MAPT
SCHEMBL7111936 0.75 NPC1 (0.52) NPC1L3MBTL1TDP1GLALMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6667341-B2 Amidomethyl esters, carbonylmercaptomethyl esters, keto-containing esters, amidomethyl thioesters, amidomethyl amides, and methylene dithioesters; anticancer agents, hemological disorders, and inherited metabolic disorders BEACON LABORATORIES, INC. 2003-12-23 US disclosed
US-20030171409-A1 Novel delta dicarbonyl compounds and methods for using the same BEACON LABORATORIES, INC, A DELAWARE CORPORATION 2003-09-11 US disclosed
US-6562995-B1 Amidomethyl esters, carbonylmercaptomethyl esters, keto-containing esters, amidomethyl thioesters, amidomethyl amides, and methylene dithioesters are disclosed. The novel compounds have two carbonyl groups connected by a linking moiety having BEACON LABORATORIES, INC. 2003-05-13 US disclosed
US-20020137775-A1 Novel delta dicarbonyl compounds and methods for using the same ERRANT GENE THERAPEUTICS, LLC 2002-09-26 US disclosed
EP-1216986-A2 Novel delta dicarbonyl compounds and methods for using same Beacon Laboratories, Inc. (US) 2002-06-26 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030171409-A1 Novel delta dicarbonyl compounds and methods for using the same HCCS, CPS1, ACAA2 NPC1 1333/4885L3MBTL1 485/4885TDP1 3643/4885
US-20020137775-A1 Novel delta dicarbonyl compounds and methods for using the same HCCS, CPS1, ACAA2 NPC1 1333/4885L3MBTL1 485/4885TDP1 3643/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.